Abeona Therapeutics Inc.

NASDAQ:ABEO

Biotechnology

Healthcare
$2.73 +1.06%

+$0.06 today

Market cap
$156.01M
Beta
1.35
P/E (TTM)
4.9
EPS (TTM)
$1.17
52W Low $4.00High $7.54

Volume 1.71M

Average 1.12M

ABEO Other Current Assets

Current assets not reported separately, such as prepaid expenses.

Abeona Therapeutics Inc.NASDAQ: ABEO

Other Current Assets · Q1 FY2026 · quarter ended Mar 2026

Other current assets falls 16.9% from a year ago

Other current assets stood at $1.95M at the end of Q1 FY2026, down 16.9% from a year earlier and up 50.8% from the prior quarter. Over 3 fiscal years it compounded at +19.3% a year.

Context

  • Other current assets amounted to 1.0% of total assets at the end of Q1 FY2026, down 1.4 pp from a year earlier.
  • Other current assets increased in 1 of the last 3 fiscal years.

What to watch

Whether other current assets keeps falling in the next quarterly balance sheet after a -16.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.95M+50.8% QoQ
Last fiscal yearDec 2025
$1.29M-12.6% YoY
Year agoMar 2025
$2.35M-16.9% since
Other Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.9%——
1 year-12.6%——
3-year CAGR+19.3%——
5-year CAGR——
10-year CAGR——

Other Current Assets history

USD · from the balance sheet

Latest · FY2025
1.29M USD
Year-over-year change
-12.6%
4-year CAGR
+9.8%

Other Current Assets vs competitors

How ABEO compares with its peers on the latest reported figures

  • ABEO's Mar 2026 other current assets of $1.95M is the 7th highest of the 10 companies compared; the peer median is $3.86M.
  • Its year-over-year change of -16.9% is the 4th highest of 10, against a peer median of -34.1%.
  • Other current assets amounts to 1.0% of total assets for ABEO, versus a peer median of 1.7%.
ABEO Competitors Peer median
Other Current Assets for ABEO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PBYIPuma Biotechnology, Inc.Mar 2026$14.33M +329.6%+27.0%7.4%
ASMBAssembly Biosciences, Inc.Mar 2026$5.56M +35.7%+163.2%2.4%
HUMAHumacyte, Inc.Mar 2026$4.7M +100.2%+12.5%4.3%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$4.16M -89.2%-17.0%1.7%
VYGRVoyager Therapeutics, Inc.Mar 2026$3.86M -45.5%+1.9%1.8%
FHTXFoghorn Therapeutics Inc.Mar 2026$3.18M -34.1%-8.1%1.4%
ABEOAbeona Therapeutics Inc.Mar 2026$1.95M -16.9%+19.3%1.0%
SGMTSagimet Biosciences Inc.Mar 2026$650K -26.8%+141.9%0.6%
TNYATenaya Therapeutics, Inc.Mar 2026$25K -98.0%+3.0%0.0%
ELDNEledon Pharmaceuticals, Inc.Mar 2026$9K -83.6%-26.8%0.0%
Peer median (excluding ABEO) $3.86M-34.1%+3.0%1.7%

Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents32.94M14.22M14.47M23.36M78.44M
Short-term Investments12.09M37.93M37.75M74.36M112.97M
Net Receivables3M188K2.44M1.65M6.72M
Inventory00005.49M
Other Current Assets891K762K338K1.48M1.29M
Total Current Assets56.29M53.1M55.74M100.85M204.91M
Property, Plant & Equipment (Net)21.74M11.07M7.99M7.98M13.88M
Goodwill00000
Intangible Assets1.38M0000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets168K43K277K96K781K
Total Non-current Assets23.29M11.12M8.27M8.08M14.66M
Total Assets79.59M64.21M64M108.93M219.57M
Account Payables4.33M1.81M1.86M3.44M7.89M
Short-term Debt0005.93M12.22M
Tax Payables00000
Deferred Revenue296K0000
Other Current Liabilities1.79M2.8M3.69M4.46M5.64M
Total Current Liabilities16.62M7.78M13.42M16.59M29.57M
Long-term Debt00013.04M7.81M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities13.04M23.82M31.35M32.01M18.9M
Total Non-current Liabilities20.6M29.67M35.75M48.31M30.78M
Total Liabilities37.22M37.45M49.18M64.9M60.35M
Common Stock1.47M177K265K457K550K
Retained Earnings(655.64M)(695.34M)(749.52M)(813.26M)(742.08M)
Accumulated OCI(27K)(129K)(66K)8K138K
Other Stockholders Equity00000
Minority Interest00000
Total Equity42.37M26.76M14.83M44.03M159.22M
Total Debt9.38M7.63M5.4M23.05M24.97M
Net Debt(23.56M)(6.59M)(9.07M)(309K)(53.47M)

Abeona Therapeutics Inc.

NASDAQ:ABEO

Intrinsic Alpha fair value

Locked

Current Price

$2.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.